Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity

Molecular Metabolism

Volumn 5, Issue 2, 2016, Pages 113-121

  Sparling, David P ^a   Yu, Junjie ^a   Kim, KyeongJin ^a   Zhu, Changyu ^a   Brachs, Sebastian ^b   Birkenfeld, Andreas L ^c,d   Pajvani, Utpal B ^a  

^a Columbia University ^*  (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Insulin resistance; Notch; secretase complex

Indexed keywords

DIBENZAZEPINE DERIVATIVE; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; IMMUNOGLOBULIN J RECOMBINATION SIGNAL SEQUENCE BINDING PROTEIN; INSULIN; NICASTRIN; NOTCH RECEPTOR;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL FUNCTION; CONTROLLED STUDY; ENZYME ACTIVITY; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; IN VITRO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIVER CELL; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84958052430     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2015.11.006     Document Type: Article

References (52)

1. Walker C.G., Zariwala M.G., Holness M.J., Sugden M.C. Diet, obesity and diabetes: a current update. Clinical Science 2007, 112:93-111.
2. Cinti S. Between brown and white: novel aspects of adipocyte differentiation. Annals of Medicine 2011, 43:104-115.
3. Axelrod J.D. Delivering the lateral inhibition punchline: it's all about the timing. Science Signaling 2010, 3:pe38.
4. Chillakuri C.R., Sheppard D., Lea S.M., Handford P.A. Notch receptor-ligand binding and activation: insights from molecular studies. Seminars in Cell & Developmental Biology 2012, 23:421-428.
5. Swiatek P.J., Lindsell C.E., del Amo F.F., Weinmaster G., Gridley T. Notch1 is essential for postimplantation development in mice. Genes & Development 1994, 8:707-719.
6. Chan S.M., Weng A.P., Tibshirani R., Aster J.C., Utz P.J. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 2007, 110:278-286.
7. Bolos V., Grego-Bessa J., de la Pompa J.L. Notch signaling in development and cancer. Endocrine Reviews 2007, 28:339-363.
8. Andersson E.R., Lendahl U. Therapeutic modulation of Notch signalling-are we there yet?. Nature Reviews Drug Discovery 2014, 13:357-378.
9. Aster J.C., Blacklow S.C. Targeting the Notch pathway: twists and turns on the road to rational therapeutics. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2012, 30:2418-2420.
10. De Strooper B., Annaert W. Novel research horizons for presenilins and gamma-secretases in cell biology and disease. Annual Review of Cell and Developmental Biology 2010, 26:235-260.
11. Haapasalo A., Kovacs D.M. The many substrates of presenilin/gamma-secretase. Journal of Alzheimer's Disease: JAD 2011, 25:3-28.
12. Li T., Ma G., Cai H., Price D.L., Wong P.C. Nicastrin is required for assembly of presenilin/gamma-secretase complexes to mediate Notch signaling and for processing and trafficking of beta-amyloid precursor protein in mammals. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2003, 23:3272-3277.
13. Shen J., Bronson R.T., Chen D.F., Xia W., Selkoe D.J., Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell 1997, 89:629-639.
14. Pajvani U.B., Shawber C.J., Samuel V.T., Birkenfeld A.L., Shulman G.I., Kitajewski J., et al. Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. Nature Medicine 2011, 17:961-967.
15. Pajvani U.B., Qiang L., Kangsamaksin T., Kitajewski J., Ginsberg H.N., Accili D. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nature Medicine 2013.
16. Fukuda D., Aikawa E., Swirski F.K., Novobrantseva T.I., Kotelianski V., Gorgun C.Z., et al. Notch ligand delta-like 4 blockade attenuates atherosclerosis and metabolic disorders. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:E1868-E1877.
17. Bi P., Shan T., Liu W., Yue F., Yang X., Liang X.R., et al. Inhibition of Notch signaling promotes browning of white adipose tissue and ameliorates obesity. Nature Medicine 2014, 20:911-918.
18. Lee K.Y., Russell S.J., Ussar S., Boucher J., Vernochet C., Mori M.A., et al. Lessons on conditional gene targeting in mouse adipose tissue. Diabetes 2013, 62:864-874.
19. Tabuchi K., Chen G., Sudhof T.C., Shen J. Conditional forebrain inactivation of nicastrin causes progressive memory impairment and age-related neurodegeneration. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2009, 29:7290-7301.
20. Plum L., Lin H.V., Dutia R., Tanaka J., Aizawa K.S., Matsumoto M., et al. The obesity susceptibility gene Cpe links FoxO1 signaling in hypothalamic pro-opiomelanocortin neurons with regulation of food intake. Nature Medicine 2009, 15:1195-1201.
21. van Es J.H., van Gijn M.E., Riccio O., van den Born M., et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005, 435:959-963.
22. Loffler M.G., Birkenfeld A.L., Philbrick K.M., Belman J.P., Habtemichael E.N., Booth C.J., et al. Enhanced fasting glucose turnover in mice with disrupted action of TUG protein in skeletal muscle. The Journal of Biological Chemistry 2013, 288:20135-20150.
23. Milano J., McKay J., Dagenais C., Foster-Brown L., Pognan F., Gadient R., et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicological Sciences: an Official Journal of the Society of Toxicology 2004, 82:341-358.
24. Garces C., Ruiz-Hidalgo M.J., Font de Mora J., Park C., Miele L., Goldstein J., et al. Notch-controls the expression of fatty acid-activated transcription factors and is required for adipogenesis. Journal of Biological Chemistry 1997, 272:29729-29734.
25. Oka C., Nakano T., Wakeham A., de la Pompa J.L., Mori C., Sakai T., et al. Disruption of the mouse RBP-kappa gene results in early embryonic death. Development 1995, 121:3291-3301.
26. Chung H.M., Struhl G. Nicastrin is required for presenilin-mediated transmembrane cleavage in Drosophila. Nature Cell Biology 2001, 3:1129-1132.
27. Yu G., Nishimura M., Arawaka S., Levitan D., Zhang L., Tandon A., et al. Nicastrin modulates presenilin-mediated notch/glp-signal transduction and betaAPP processing. Nature 2000, 407:48-54.
28. Zhang Y.W., Luo W.J., Wang H., Lin P., Vetrivel K.S., Liao F., et al. Nicastrin is critical for stability and trafficking but not association of other presenilin/gamma-secretase components. The Journal of Biological Chemistry 2005, 280:17020-17026.
29. Shah S., Lee S.F., Tabuchi K., Hao Y.H., Yu C., LaPlant Q., et al. Nicastrin functions as a gamma-secretase-substrate receptor. Cell 2005, 122:435-447.
30. Urs S., Turner B., Tang Y., Rostama B., Small D., Liaw L. Effect of soluble Jagged1-mediated inhibition of Notch signaling on proliferation and differentiation of an adipocyte progenitor cell model. Adipocyte 2012, 1:46-57.
31. Wang Y., Rovira M., Yusuff S., Parsons M.J. Genetic inducible fate mapping in larval zebrafish reveals origins of adult insulin-producing beta-cells. Development 2011, 138:609-617.
32. Fischer A., Gessler M. Delta-Notch-and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors. Nucleic Acids Research 2007, 35:4583-4596.
33. Del Monte G., Grego-Bessa J., Gonzalez-Rajal A., Bolos V., De La Pompa J.L. Monitoring Notch1 activity in development: evidence for a feedback regulatory loop. Developmental Dynamics: an Official Publication of the American Association of Anatomists 2007, 236:2594-2614.
34. Wang Q.A., Tao C., Gupta R.K., Scherer P.E. Tracking adipogenesis during white adipose tissue development, expansion and regeneration. Nature Medicine 2013, 19:1338-1344.
35. Urs S., Harrington A., Liaw L., Small D. Selective expression of an aP2/fatty acid binding protein 4-Cre transgene in non-adipogenic tissues during embryonic development. Transgenic Research 2006, 15:647-653.
36. Martens K., Bottelbergs A., Baes M. Ectopic recombination in the central and peripheral nervous system by aP2/FABP4-Cre mice: implications for metabolism research. FEBS Letters 2010, 584:1054-1058.
37. Mullican S.E., Tomaru T., Gaddis C.A., Peed L.C., Sundaram A., Lazar M.A. A novel adipose-specific gene deletion model demonstrates potential pitfalls of existing methods. Molecular Endocrinology 2013, 27:127-134.
38. Chartoumpekis D.V., Palliyaguru D.L., Wakabayashi N., Khoo N.K., Schoiswohl G., O'Doherty R.M., et al. Notch intracellular domain overexpression in adipocytes confers lipodystrophy in mice. Molecular Metabolism 2015, 4:543-550.
39. Shawber C., Nofziger D., Hsieh J.J., Lindsell C., Bogler O., Hayward D., et al. Notch signaling inhibits muscle cell differentiation through a CBF1-independent pathway. Development 1996, 122:3765-3773.
40. Bluher M., Michael M.D., Peroni O.D., Ueki K., Carter N., Kahn B.B., et al. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Developmental Cell 2002, 3:25-38.
41. Morley T.S., Xia J.Y., Scherer P.E. Selective enhancement of insulin sensitivity in the mature adipocyte is sufficient for systemic metabolic improvements. Nature Communications 2015, 6:7906.
42. Kusminski C.M., Gallardo-Montejano V.I., Wang Z.V., Hegde V., Bickel P.E., Dhurandhar N.V., et al. E4orf1 induction in adipose tissue promotes insulin-independent signaling in the adipocyte. Molecular Metabolism 2015, 4:653-664.
43. Pajvani U.B., Scherer P.E. Adiponectin: systemic contributor to insulin sensitivity. Current Diabetes Reports 2003, 3:207-213.
44. Savage D.B., Semple R.K. Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Current Opinion in Lipidology 2010, 21:329-336.
45. Birkenfeld A.L., Shulman G.I. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 2014, 59:713-723.
46. Lin S., Shen H., Jin B., Gu Y., Chen Z., Cao C., et al. Brief report: blockade of Notch signaling in muscle stem cells causes muscular dystrophic phenotype and impaired muscle regeneration. Stem Cells 2012, 31:823-828.
47. Chen J.Y., Feng L., Zhang H.L., Li J.C., Yang X.W., Cao X.L., et al. Differential regulation of bone marrow-derived endothelial progenitor cells and endothelial outgrowth cells by the Notch signaling pathway. PloS One 2012, 7:e43643.
48. Geisler F., Strazzabosco M. Emerging roles of Notch signaling in liver disease. Hepatology 2015, 61:382-392.
49. Takebe N., Nguyen D., Yang S.X. Targeting Notch signaling pathway in cancer: clinical development advances and challenges. Pharmacology & Therapeutics 2014, 141:140-149.
50. Wu Y., Cain-Hom C., Choy L., Hagenbeek T.J., de Leon G.P., et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010, 464:1052-1057.
51. Funahashi Y., Hernandez S.L., Das I., Ahn A., Huang J., Vorontchikhina M., et al. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Research 2008, 68:4727-4735.
52. Valenti L., Mendoza R.M., Rametta R., Maggioni M., Kitajewski C., Shawber C.J., et al. Hepatic Notch signaling correlates with insulin resistance and non-alcoholic fatty liver disease. Diabetes 2013, 62:4052-4062.